The elimination of the DEA X-waiver requirement in December 2022 removed the federal barrier to prescribing buprenorphine for opioid use disorder, but state-level restrictions on dispensing remain significant.
What changed federally
The Consolidated Appropriations Act of 2023 eliminated the DATA 2000 X-waiver requirement. Any DEA-registered practitioner with Schedule III authority can now prescribe buprenorphine for OUD without special certification. This significantly expanded the prescriber pool — but dispensing rules for pharmacists remain state-governed.
PDMP requirements
Most states require pharmacists to check the prescription drug monitoring program before dispensing buprenorphine. Some states require prospective PDMP review for every dispensing. Others require it only on initial fills or when clinical indicators suggest concern.
Quantity and day supply limits
Several states impose quantity limits on buprenorphine prescriptions — particularly for initial fills. These vary significantly. Check your state board’s controlled substance dispensing rules for current limits.
Prior authorization requirements
Some state Medicaid programs require prior authorization for buprenorphine products. This affects both the prescriber and the pharmacist workflow. Know your state’s Medicaid PA requirements before dispensing to Medicaid patients.
Pharmacist refusal protections
Some states have enacted laws protecting pharmacists from employer retaliation for dispensing buprenorphine prescriptions that are valid on their face. Know your state’s protections before dispensing.
Verify state requirements
Buprenorphine dispensing rules are complex and overlap federal and state authority. Verify current requirements with your state board of pharmacy and state PDMP program before dispensing.